Rapamycin 29-Enols
AssigneeWyeth
InventorsTianmin Zhu, Mahdi B. Fawzi
Life of this patent
Estimating the term…
Abstract
This invention provides non-immunosuppressive rapamycin 29-enols, which are useful as neurotrophic agents, in the treatment of solid tumors, and vascular disease.
Claims21
A compound which is a rapamycin 29-enol or a pharmaceutically acceptable salt thereof.
A method of stimulating nerve cell growth in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin 29-enol.
A method of stimulating nerve regeneration in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin 29-enol.
A method of stimulating the growth of damaged peripheral nerves in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin 29-enol.
A method of treating or inhibiting a neurodegenerative disorder in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin 29-enol.
A method of treating peripheral nerve damage in a mammal in need thereof, which comprises administering to said mammal an effective amount of a rapamycin 29-enol.
A method of treating a solid tumor in a mammal in need thereof, which comprises providing to said mammal an effective amount of a rapamycin 29-enol.
A method of treating or inhibiting a hyperproliferative vascular disorder which comprises providing to said mammal an effective amount of a rapamycin 29-enol.
A pharmaceutical composition which comprises a rapamycin 29-enol and a pharmaceutical carrier.
A compound which is (2E,4S,6R)-6-[(5S,6R)-5-hydroxy-6-methoxy-4-methyl-2,3,7-trioxabicyclo[2.2.1]hept-1-yl]-4-methylhept-2-enal.
Dependencies are inferred from the claim text.